Effect of Potassium‐Competitive Acid Blockers on Upper Gastrointestinal Bleeding in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study
Open Access
- 27 April 2025
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (7) , 1686-1694
Abstract
Background and Aim: Proton pump inhibitors (PPIs) are the drug of choice to prevent upper gastrointestinal (UGI) bleeding in patients receiving dual antiplatelet therapy (DAPT); however, unmet needs remain. Potassium‐competitive acid blockers (P‐CABs) are novel acid‐suppressive drugs that have emerged as potential alternatives. We evaluated the effectiveness of P‐CAB in reducing the risk of UGI bleeding in patients receiving DAPT after percutaneous coronary intervention (PCI).Methods: This retrospective cohort study included patients with PCI on DAPT between January 2019 and January 2023 using the Korean nationwide health claims database. The primary outcome was admission for UGI bleeding within 6 months of PCI. A multivariate Cox regression model was used to evaluate UGI bleeding risk based on PPIs and P‐CAB use.Results: Of the 210 447 patients who underwent PCI on DAPT (mean age, 65.5 years; 74.7% men), 4.6% and 47.5% patients were prescribed P‐CABs and PPIs, respectively. Overall, 0.3% of patients experienced UGI bleeding within 6 months of PCI. P‐CAB users had a reduced risk of UGI bleeding (adjusted hazard ratio, 0.59; 95% confidence interval, 0.38–0.92; p = 0.019) compared with patients not receiving P‐CAB or PPI. No significant difference was observed between the P‐CAB and PPI users (p > 0.05).Conclusions: Among Korean patients undergoing PCI with DAPT, P‐CABs reduced UGI bleeding comparably to PPIs. These findings suggest that P‐CABs are potential alternatives to PPIs for preventing UGI bleeding.Keywords
Funding Information
- Daewoong Pharmaceutical Company (9‐2023‐0064)
- Ministry of Science and ICT, South Korea (RS‐2024‐00345524)
This publication has 36 references indexed in Scilit:
- Proton Pump Inhibitor for Gastrointestinal Bleeding in Patients with Myocardial Infarction on Dual-Antiplatelet Therapy: A Nationwide Cohort StudyJournal of Epidemiology and Global Health, 2024
- AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert ReviewGastroenterology, 2022
- 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive SummaryJACC, 2022
- Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database studyJournal of Cardiology, 2020
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or AspirinGastroenterology, 2019
- Proton Pump Inhibitors Are Underprescribed in Patients Discharged on Dual Antiplatelet Therapy After Acute Coronary SyndromeGastroenterology, 2018
- No Significant Association Between Proton Pump Inhibitor Use and Risk of Stroke After Adjustment for Lifestyle Factors and IndicationGastroenterology, 2018
- Update on the Use of Vonoprazan: A Competitive Acid BlockerGastroenterology, 2018
- The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological AssociationGastroenterology, 2017
- Vonoprazan: First Global ApprovalDrugs, 2015